Company

In June 2021, the Company obtained interstate reference material status for eight CRMs recognized by several CIS and EAEU countries. That autumn, at the VI All-Russian GMP Conference, NCSS signed an agreement with the RAS Federal Research Center for Biotechnology on the development of reference materials for biotechnological medicines—a major step toward more complex, science-intensive areas. Construction of a laboratory and production complex for RM development also began in 2021, and 26 state reference materials were developed jointly with FSI "GILS and GP."

2022 was a year of scaling for NCSS. The government grant program supporting reference material development received a regulatory framework under Russian Government Resolution No. 208 and subsequent amendments. By December 2022, approximately 150 reference materials had been developed and approved in Russia, with roughly one third attributable to the Center. That same year, Rosstandart approved the first impurity CRMs produced by NCSS.

In 2023, NCSS entered a phase of active growth. By then, the organization was seen as one of the key tools for import substitution in pharmaceutical quality control. In 2023, construction of the new laboratory complex was completed and 80 CRMs were developed.

In 2024, NCSS consolidated the results of previous years. By May, the company reported that the number of certified state reference materials had grown to 148, with about 100 more in progress. On September 17, 2024, NCSS passed an inspection by the Russian Ministry of Industry and Trade and received GMP certification; on November 22 it successfully confirmed compliance of its quality management system with GOST R ISO 9001:2015. The year ended with a fivefold increase in sales volume, expansion of laboratory services, and major contracts for CRM development and drug testing.

In 2025, NCSS took another step from CRM developer to a broader provider of solutions for analytical infrastructure. In autumn, the company reported that the register included 250 different types of CRMs of its manufacture; in December it summarized the year with more than 250 developed and certified RMs, 74 recognized as interstate. A flagship event was the launch of the first domestic HPLC chromatography column under the Calibra Chrom brand, developed with Belarusian partners; deliveries began in October 2025. Thus 2025 became a year not only of expanding the reference material portfolio but also of entering a new field directly linked to laboratory import substitution.

A key event in 2026 was the opening of a full-cycle R&D center focused on developing approaches to the synthesis of active pharmaceutical ingredients (APIs) and creating finished dosage forms. The launch of the R&D center is part of systematic work to develop full-cycle pharmaceutical development and strengthen the technological independence of the industry. As of 2026, NCSS's reference material portfolio comprises more than 270 items.